SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Anebulo Pharmaceuticals, Inc. (ANEB) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+1100%).
- Analyst consensus target $6.00 (+1100% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ANEB
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.25
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$6.00 (+1100%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-0.01 |
$0.00 |
$-174.64K |
- |
| 2021 |
$-2.83 |
$0.00 |
$-30.25M |
- |
| 2022 |
$-0.29 |
$0.00 |
$-6.83M |
- |
| 2023 |
$-0.47 |
$0.00 |
$-11.73M |
- |
| 2024 |
$-0.32 |
$0.00 |
$-8.2M |
- |
| 2025 |
$-0.25 |
$0.00 |
$-8.48M |
- |
